Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience

BACKGROUND: Despite all the scientific progress that has been made on understanding the disease, prognosis for patients with relapsed and refractory Hodgkin's lymphoma remains poor and the treatment is palliative in the majority of the cases. Thus, the aim of this study was to present the resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocha, Talita Máira Bueno da Silveira da, Fortier, Sergio Costa, Fischer, Thais Rodrigues da Cunha, Perini, Guilherme Fleury, Gaiolla, Rafael Dezen, Fogliatto, Laura, Delamain, Marcia Torresan, Costa, Andressa Fragoso da, Castro, Nelson Siqueira de, Barretos, Wolney Gois, Souza, Cármino Antonio de, Buccheri, Valéria, Chiattone, Carlos Sérgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567422/
https://www.ncbi.nlm.nih.gov/pubmed/28830600
http://dx.doi.org/10.1016/j.bjhh.2017.03.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567422/
https://www.ncbi.nlm.nih.gov/pubmed/28830600
http://dx.doi.org/10.1016/j.bjhh.2017.03.008

Ejemplares similares